Immutep Reports Clinical Data From INSIGHT-003 Trial At ESMO Congress 2023
Portfolio Pulse from Benzinga Newsdesk
Immutep has reported promising efficacy and tolerability from its INSIGHT-003 trial at the ESMO Congress 2023. The trial involved efti plus anti-PD-1 therapy and doublet chemotherapy as first-line therapy in metastatic non-squamous non-small cell lung cancer. The trial showed a 71.4% Overall Response Rate, 90.5% Disease Control Rate, 10.1-month median Progression Free Survival, and median Overall Survival that has not been reached.
October 24, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immutep's INSIGHT-003 trial results show promising efficacy and tolerability, which could potentially boost the company's stock in the short term.
The positive results from Immutep's INSIGHT-003 trial indicate a potential breakthrough in the treatment of metastatic non-squamous non-small cell lung cancer. This could lead to increased investor confidence and a potential rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100